India’s young population, with a median age of just 28, is one of the biggest reasons our cancer burden remains well below that of developed nations today.
But that advantage is temporary.
As India ages, annual cancer cases are expected to rise sharply over the next two decades. The challenge isn’t just treating more patients – it’s building the research, manufacturing and clinical infrastructure before that wave arrives. This is why we believe advanced therapies like CAR-T, which harness a patient’s own immune system to fight cancer, could become one of the defining healthcare innovations of the coming decades.
In our latest blog, we dive into the evolution of cancer treatment, why CAR-T therapy is changing the global standard of care, and why we are excited to partner with Immuneel Therapeutics as it works to make this breakthrough technology more accessible in India. Read our write-up below! ⬇️
